10:44 AM EDT, 08/15/2024 (MT Newswires) -- Novo Nordisk A/S ( NVO ) submitted a notice of appeal to the US Court of Appeals for the Third Circuit after a federal district judge rejected its arguments against the Medicare Drug Price Negotiation Program.

The appeal was filed one day before the Centers for Medicare & Medicaid Services published the first 10 negotiated drug prices under the new program.

Price: 136.28, Change: +1.86, Percent Change: +1.38